Mecanismos de resistencia a fluconazol expresados por Candida glabrata: una situación para considerar en la terapéutica

Resistance mechanisms to fluconazole expressed by Candida glabrata: a situation to consider in therapy

Mecanismos de resistência a fluconazol expressos por Candida glabrata: uma situação a considerar na terapêutica

  • Leidy Yurani Cárdenas Parra Universidad de Caldas y Universidad Católica de Manizales (Colombia)
  • Jorge Enrique Pérez Cárdenas Universidad de Caldas (Colombia)
Palabras clave: Candida glabrata, Candida, resistencia, azoles, fluconazol
Key-words: Candida glabrata, Candida, resistance, azoles, fluconazole
Palavras chave: Candida glabrata, Candida, resistência, azóis, fluconazol

Resumen

Abstract

Resumo

Bibliografía

1. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14(11):e954-66. https://doi.org/10.1016/j.ijid.2010.04.006


2. Yeşilkaya A, Azap Ö, Aydın M, Akçil Ok M. Epidemiology, species distribution, clinical characteristics and mortality of candidaemia in a tertiary care university hospital in Turkey, 2007-2014. Mycoses. 2017;60(7):433-9. https://doi.org/10.1111/myc.12618


3. Savastano C, de Oliveira Silva E, Gonçalves LL, Nery JM, Silva NC, Dias ALT. Candida glabrata among Candida spp. from environmental health practitioners of a Brazilian Hospital. Braz J Microbiol Publ Braz Soc Microbiol. 2016;47(2):367-72. https://doi.org/10.1016/j.bjm.2015.05.001


4. Goemaere B, Becker P, Van Wijngaerden E, Maertens J, Spriet I, Hendrickx M, et al. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. Mycoses. 2018;61(2):127-33. https://doi.org/10.1111/myc.12714


5. Sasso M, Roger C, Sasso M, Poujol H, Barbar S, Lefrant J-Y, et al. Changes in the distribution of colonising and infecting Candida spp. isolates, antifungal drug consumption and susceptibility in a French intensive care unit: A 10-year study. Mycoses. 2017;60(12):770-80. https://doi.org/10.1111/myc.12661


6. de Bedout C, Gómez BL. Candida and candidiasis: the challenge continues for an early diagnosis. Infectio. 2010;14:s159-71.


7. Valle GMM del. Candida glabrata: un patógeno emergente. Biociencias. 2016;10(1):89-102. https://doi.org/10.18041/2390-0512/bioc..1.2859


8. Rodríguez AZ, Gómez C de B, Restrepo CAA, Parra HH, Arteaga MA, Moreno AR, et al. [Susceptibility to fluconazole and voriconazole of Candida species isolated from intensive care units patients in Medellin, Colombia (2001-2007)]. Rev Iberoam Micol. 2010;27(3):125-9. https://doi.org/10.1016/j.riam.2010.04.001


9. Magalhães YC, Bomfim MRQ, Melônio LC, Ribeiro PCS, Cosme LM, Rhoden CR, et al. Clinical significance of the isolation of Candida species from hospitalized patients. Braz J Microbiol Publ Braz Soc Microbiol. 2015;46(1):117-23. https://doi.org/10.1590/S1517-838246120120296


10. Tapia P C. Candida glabrata. Rev Chil Infectol. 2008;25(4):293-293. http://dx.doi.org/10.4067/S0716-10182008000400009


11. Olaechea P, Lerma FA, Martínez MP, Ordeñana JI, López-Pueyo MJ, Betolaza IS, et al. Evolución del consumo de antifúngicos en pacientes críticos. Estudio multicéntrico observacional, 2006-2010. Enferm Infecc Microbiol Clin. 2012;30(8):435-40. https://doi.org/10.1016/j.eimc.2012.02.006


12. Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58 Suppl 2:2-13. https://doi.org/10.1111/myc.12330


13. Florez J, Armijo JA, De Cost MA. Reacciones adversas a los medicamentos y farmacovigilancia. En: Flórez J, Armijo JA, editores. Farmacología humana. 5.. ed. Barcelona: Masson; 2008. p. 129-46.


14. Isaza G, Fuentes J, Marulanda T, Buriticá O, Machado J, Moncada J. Generalidades de farmacología. En: Isaza G, Fuentes J, Marulanda T, et al., editores. Fundamentos de farmacología en terapéutica. 6.. ed. Bogotá: Celsus; 2014. p. 27-31.


15. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 21 de julio de 2009;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097


16. Deorukhkar SC, Saini S. Virulence factors attributed to pathogenicity of non albicans Candida species isolated from Human Immunodeficiency virus infected patients with oropharyngeal candidiasis. Ann Pathol Lab Med. 2015;2(2):A62-66. https://doi.org/10.1155/2014/456878


17. Ahmad KM, Kokošar J, Guo X, Gu Z, Ishchuk OP, Piškur J. Genome structure and dynamics of the yeast pathogen Candida glabrata. FEMS Yeast Res. 2014;14(4):529-35. https://doi.org/10.1111/1567-1364.12145


18. Muller H, Hennequin C, Gallaud J, Dujon B, Fairhead C. The asexual yeast Candida glabrata maintains distinct a and alpha haploid mating types. Eukaryot Cell. 2008;7(5):848-58. https://doi.org/10.1128/EC.00456-07


19. Bairwa G, Rasheed M, Taigwal R, Sahoo R, Kaur R. GPI (glycosylphosphatidylinositol)-linked aspartyl proteases regulate vacuole homoeostasis in Candida glabrata. Biochem J. 2014;458(2):323-34. https://doi.org/10.1042/BJ20130757


20. Lesage G, Bussey H. Cell Wall Assembly in Saccharomyces cerevisiae. Microbiol Mol Biol Rev. 2006;70(2):317-43. https://doi.org/10.1128/MMBR.00038-05


21. Pontón J. La pared celular de los hongos y el mecanismo de acción de la anidulafungina. Rev Iberoam Micol. 2008;25(2):78-82. https://doi.org/10.1016/S1130-1406(08)70024-X


22. Chaffin WL, López-Ribot JL, Casanova M, Gozalbo D, Martínez JP. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol Mol Biol Rev MMBR. 1998;62(1):130-80


23. Okada H, Abe M, Asakawa-Minemura M, Hirata A, Qadota H, Morishita K, et al. Multiple functional domains of the yeast l,3-beta-glucan synthase subunit Fks1p revealed by quantitative phenotypic analysis of temperature-sensitive mutants. Genetics. 2010;184(4):1013-24. https://doi.org/10.1534/genetics.109.109892


24. Spanova M, Czabany T, Zellnig G, Leitner E, Hapala I, Daum G. Effect of lipid particle biogenesis on the subcellular distribution of squalene in the yeast Saccharomyces cerevisiae. J Biol Chem. 2010;285(9):6127-33. https://doi.org/10.1074/jbc.M109.074229


25. Base de datos en farmacología Drugbank. Fluconazole [Internet]. Washington: FDA. 2018 [citado 2018 oct 7]. Disponible en: https://www.drugbank.ca/drugs/DB00196


26. Tuck SF, Patel H, Safi E, Robinson CH. Lanosterol 14 alpha-demethylase (P45014DM): effects of P45014DM inhibitors on sterol biosynthesis downstream of lanosterol. J Lipid Res. 1991;32(6):893-902.


27. Fonseca E, Silva S, Rodrigues CF, Alves CT, Azeredo J, Henriques M. Effects of fluconazole on Candida glabrata biofilms and its relationship with ABC transporter gene expression. Biofouling. 2014;30(4):447-57. https://doi.org/10.1080/08927014.2014.886108


28. Castanheira M, Messer SA, Jones RN, Farrell DJ, Pfaller MA. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int J Antimicrob Agents. 2014;44(4):320-6. https://doi.org/10.1016/j.ijantimicag.2014.06.007


29. Roetzer A, Gratz N, Kovarik P, Schüller C. Autophagy supports Candida glabrata survival during phagocytosis. Cell Microbiol. 2010;12(2):199-216. https://doi.org/10.1111/j.1462-5822.2009.01391


30. Chelsea M, Armstrong A, Armstrong E. Principios de quimioterapia. En: Brunton L, Chabner B, Knollman B, editores. Bases fisiopatológicas del tratamiento farmacológico. 4.. ed. Barcelona: Lippincott Williams and Wilkins; 2017. p. 661-74.


31. Nabili M, Abdollahi Gohar A, Badali H, Mohammadi R, Moazeni M. Amino acid substitutions in Erg11p of azole-resistant Candida glabrata: Possible effective substitutions and homology modelling. J Glob Antimicrob Resist. 2016;5:42-6. https://doi.org/10.1016/j.jgar.2016.03.003


32. Morace G, Perdoni F, Borghi E. Antifungal drug resistance in Candida species. J Glob Antimicrob Resist. 2014;2(4):254-9. https://doi.org/10.1016/j.jgar.2014.09.002


33. Morio F, Jensen RH, Le Pape P, Arendrup MC. Molecular basis of antifungal drug resistance in yeasts. Int J Antimicrob Agents. 2017;50(5):599-606. https://doi.org/10.1016/j.ijantimicag.2017.05.012


34. Flórez J, Peralta G, Mediavilla A. Enfermedades infecciosas. En: Flórez J, Armijo JA, editores. Farmacología humana. 5.. ed. Barcelona: Masson; 2008. p. 1301-16.


35. Sheppard D, Lampiris H. Fármacos quimioterapéuticos. En: Katzung BG, Masters SB, Trevor AJ, editores. Farmacología básica y clínica. 12.. ed. México: McGraw-Hill; 2013. p. 849-60.


36. Silva V, Díaz MC, Febré N. Vigilancia de la resistencia de levaduras a antifúngicos. Rev Chil Infectol. 2002;19 (suppl 2):149-56. http://dx.doi.org/10.4067/S0716-10182002019200016


37. Becher R, Wirsel SGR. Fungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens. Appl Microbiol Biotechnol. 2012;95(4):825-40. https://doi.org/10.1007/s00253-012-4195-9


38. Morace G, Perdoni F, Borghi E. Antifungal drug resistance in Candida species. J Glob Antimicrob Resist. 2014;2(4):254-9. https://doi.org/10.1016/j.jgar.2014.09.002


39. Biswas C, Chen SC-A, Halliday C, Kennedy K, Playford EG, Marriott DJ, et al. Identification of genetic markers of resistance to echinocandins, azoles and 5-fluorocytosine in Candida glabrata by next-generation sequencing: a feasibility study. Clin Microbiol Infect. 2017;23(9):676.e7-676.e10. https://doi.org/10.1016/j.cmi.2017.03.014


40. Morio F, Jensen RH, Le Pape P, Arendrup MC. Molecular basis of antifungal drug resistance in yeasts. Int J Antimicrob Agents. 2017;50(5):599-606. https://doi.org/10.1016/j.ijantimicag.2017.05.012


41. Silva DB dos S, Rodrigues LMC, Almeida AA de, Oliveira KMP de, Grisolia AB. Novel point mutations in the ERG11 gene in clinical isolates of azole resistant Candida species. Mem Inst Oswaldo Cruz. 2016;111(3):192-9. https://doi.org/10.1590/0074-02760150400


42. Puri N, Manoharlal R, Sharma M, Sanglard D, Prasad R. Overcoming the heterologous bias: an in vivo functional analysis of multidrug efflux transporter, CgCdr1p in matched pair clinical isolates of Candida glabrata. Biochem Biophys Res Commun. 2011;404(1):357-63. https://doi.org/10.1016/j.bbrc.2010.11.123


43. Clinical and Laboratory Standards Institute (CLSI). Methods for antifungal disk diffusion susceptibility testing of yeasts; approved guideline-Second Edition; 2009. CLSI Document M44-A2: [Internet]. 2009. Disponible en: https://clsi.org/media/1634/m44a2_sample.pdf


44. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-Third Edition; 2008. CLSI Document M27-A3 [Internet]. 2008. Disponible en: https://clsi.org/media/1461/m27a3_sample.pdf


45. Clinical and Laboratory Standards Institute (CLSI). reference method for broth dilution antifungal susceptibility testing of yeasts; fourth informational supplement; 2012. CLSI Document M27-S4. [Internet]. 2012. Disponible en: https://clsi.org/media/1897/m27ed4_sample.pdf


46. Clinical and Laboratory Standards Institute (CLSI). Perfomance stands for antifungal susceptibility testing of yeasts; first edition; 2017. CLSI Document M60 [Internet]. 2017. Disponible en: https://clsi.org/standards/products/microbiology/documents/m60/


47. Branco J, Ola M, Silva RM, Fonseca E, Gomes NC, Martins-Cruz C, et al. Impact of ERG3 mutations and expression of ergosterol genes controlled by UPC2 and NDT80 in Candida parapsilosis azole resistance. Clin Microbiol Infect. 2017;23(8):575.e1-575.e8. https://doi.org/10.1016/j.cmi.2017.02.002


48. Tapia C. Antifúngicos y resistencia. Rev Chil Infectol. 2012;29(3):357-357. http://dx.doi.org/10.4067/S0716-10182012000300020


49. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125(1 Suppl):S3-13. https://doi.org/10.1016/j.amjmed.2011.11.001


50. Abbes S, Amouri I, Sellami H, Neji S, Trabelsi H, Cheikhrouhou F, et al. Changes in genotype and fluconazole susceptibility of isolates from patients with Candida glabrata in Tunisia. Thérapie. 2014;69(5):449-55. https://doi.org/10.2515/therapie/2014059


51. López-Ávila K, Dzul-Rosado KR, Lugo-Caballero C, Arias-León JJ, Zavala-Castro JE. Mecanismos de resistencia antifúngica de los azoles en Candida albicans: una revisión. Rev Bioméd. 2016;27(3):127-36. http://dx.doi.org/10.32776/revbiomed.v27i3.541


52. Vermitsky J-P, Edlind TD. Azole Resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-Like transcription factor. Antimicrob Agents Chemother. 2004;48(10):3773-81. https://doi.org/10.1128/AAC.48.10.3773-3781.2004


53. Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008;46(1):120-8. https://doi.org/10.1086/524071


54. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50(4):1199-203. https://doi.org/10.1128/JCM.06112-11


55. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12(4):501-17


56. Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. 2016;6(2):71-9. doi 10.1016/j.jpha.2015.11.005


57. Sakagami T, Kawano T, Yamashita K, Yamada E, Fujino N, Kaeriyama M, et al. Antifungal susceptibility trend and analysis of resistance mechanism for Candida species isolated from bloodstream at a Japanese university hospital. J Infect Chemother. 2019;25(1):34-40. https://doi.org/10.1016/j.jiac.2018.10.007


58. Rocha DAS, Sa LFR de, Pinto ACC, Junqueira M de L, Silva EM da, Borges RM, et al. Characterisation of an ABC transporter of a resistant Candida glabrata clinical isolate. Mem Inst Oswaldo Cruz. 2018;113(4):e170484. https://doi.org/10.1590/0074-02760170484


59. Szweda P, Gucwa K, Romanowska E, Dzierz Anowska-Fangrat K, Naumiuk Ł, Brillowska-Da Browska A, et al. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland. J Med Microbiol. 2015;64(6):610-9. https://doi.org/10.1099/jmm.0.000062


60. Holmes AR, Keniya MV, Ivnitski-Steele I, Monk BC, Lamping E, Sklar LA, et al. The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrob Agents Chemother. 2012;56(3):1508-15. https://doi.org/10.1128/AAC.05706-11


61. Salazar SB, Wang C, Münsterkötter M, Okamoto M, Takahashi-Nakaguchi A, Chibana H, et al. Comparative genomic and transcriptomic analyses unveil novel features of azole resistance and adaptation to the human host in Candida glabrata. FEMS Yeast Res. 2018;18(1). https://doi.org/10.1093/femsyr/fox079


62. Tsai H-F, Sammons LR, Zhang X, Suffis SD, Su Q, Myers TG, et al. Microarray and molecular analyses of the azole resistance mechanism in Candida glabrata oropharyngeal isolates. Antimicrob Agents Chemother. 2010;54(8):3308-17. https://doi.org/10.1128/AAC.00535-10


63. Hou X, Xiao M, Wang H, Yu S-Y, Zhang G, Zhao Y, et al. Profiling of PDR1 and MSH2 in Candida glabrata bloodstream isolates from a multicenter study in China. Antimicrob Agents Chemother. 2018;62(6). https://doi.org/10.1128/AAC.00153-18

Novedades
Estadísticas
Cómo citar
1.
Cárdenas Parra, Leidy Yurani; Pérez Cárdenas, Jorge Enrique. Mecanismos de resistencia a fluconazol expresados por Candida glabrata: una situación para considerar en la terapéutica. Investigación en Enfermería: Imagen y Desarrollo. 2020; 22: 1-2. Disponible en: http://ciberindex.com/c/id/2208id [acceso: 20/04/2021]
Sección
Artículos de Revisión Integrativa o Sistemática
Comentarios

DEJA TU COMENTARIO     VER 0 COMENTARIOS

Normas y uso de comentarios


Hay un total de 0 comentarios


INTRODUCIR NUEVO COMENTARIO

Para enviar un comentario, rellene los campos situados debajo. Recuerde que es obligatorio indicar un nombre y un email para enviar su comentario (el email no sera visible en el comentario).

Nombre:
e-mail:
Comentario: